TIGIT and CD96 are expressed on the surface of T cells and natural killer cells and represent targets for immune modulation (78), as blocking CD96 or TIGIT with monoclonal antibodies improves tumor control in mice, especially when used in combination with PD-1/PD-L1 blockade (79). This evidence concerns the gene CD274 and neoplasm.